Cargando…

The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils

Aggregation of amyloidogenic proteins is a characteristic of multiple neurodegenerative diseases. Atomic resolution of small molecule binding to such pathological protein aggregates is of interest for the development of therapeutics and diagnostics. Here we investigate the interaction between α-synu...

Descripción completa

Detalles Bibliográficos
Autores principales: Antonschmidt, Leif, Matthes, Dirk, Dervişoğlu, Rıza, Frieg, Benedikt, Dienemann, Christian, Leonov, Andrei, Nimerovsky, Evgeny, Sant, Vrinda, Ryazanov, Sergey, Giese, Armin, Schröder, Gunnar F., Becker, Stefan, de Groot, Bert L., Griesinger, Christian, Andreas, Loren B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474542/
https://www.ncbi.nlm.nih.gov/pubmed/36104315
http://dx.doi.org/10.1038/s41467-022-32797-w
_version_ 1784789742305411072
author Antonschmidt, Leif
Matthes, Dirk
Dervişoğlu, Rıza
Frieg, Benedikt
Dienemann, Christian
Leonov, Andrei
Nimerovsky, Evgeny
Sant, Vrinda
Ryazanov, Sergey
Giese, Armin
Schröder, Gunnar F.
Becker, Stefan
de Groot, Bert L.
Griesinger, Christian
Andreas, Loren B.
author_facet Antonschmidt, Leif
Matthes, Dirk
Dervişoğlu, Rıza
Frieg, Benedikt
Dienemann, Christian
Leonov, Andrei
Nimerovsky, Evgeny
Sant, Vrinda
Ryazanov, Sergey
Giese, Armin
Schröder, Gunnar F.
Becker, Stefan
de Groot, Bert L.
Griesinger, Christian
Andreas, Loren B.
author_sort Antonschmidt, Leif
collection PubMed
description Aggregation of amyloidogenic proteins is a characteristic of multiple neurodegenerative diseases. Atomic resolution of small molecule binding to such pathological protein aggregates is of interest for the development of therapeutics and diagnostics. Here we investigate the interaction between α-synuclein fibrils and anle138b, a clinical drug candidate for disease modifying therapy in neurodegeneration and a promising scaffold for positron emission tomography tracer design. We used nuclear magnetic resonance spectroscopy and the cryogenic electron microscopy structure of α-synuclein fibrils grown in the presence of lipids to locate anle138b within a cavity formed between two β-strands. We explored and quantified multiple binding modes of the compound in detail using molecular dynamics simulations. Our results reveal stable polar interactions between anle138b and backbone moieties inside the tubular cavity of the fibrils. Such cavities are common in other fibril structures as well.
format Online
Article
Text
id pubmed-9474542
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-94745422022-09-16 The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils Antonschmidt, Leif Matthes, Dirk Dervişoğlu, Rıza Frieg, Benedikt Dienemann, Christian Leonov, Andrei Nimerovsky, Evgeny Sant, Vrinda Ryazanov, Sergey Giese, Armin Schröder, Gunnar F. Becker, Stefan de Groot, Bert L. Griesinger, Christian Andreas, Loren B. Nat Commun Article Aggregation of amyloidogenic proteins is a characteristic of multiple neurodegenerative diseases. Atomic resolution of small molecule binding to such pathological protein aggregates is of interest for the development of therapeutics and diagnostics. Here we investigate the interaction between α-synuclein fibrils and anle138b, a clinical drug candidate for disease modifying therapy in neurodegeneration and a promising scaffold for positron emission tomography tracer design. We used nuclear magnetic resonance spectroscopy and the cryogenic electron microscopy structure of α-synuclein fibrils grown in the presence of lipids to locate anle138b within a cavity formed between two β-strands. We explored and quantified multiple binding modes of the compound in detail using molecular dynamics simulations. Our results reveal stable polar interactions between anle138b and backbone moieties inside the tubular cavity of the fibrils. Such cavities are common in other fibril structures as well. Nature Publishing Group UK 2022-09-14 /pmc/articles/PMC9474542/ /pubmed/36104315 http://dx.doi.org/10.1038/s41467-022-32797-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Antonschmidt, Leif
Matthes, Dirk
Dervişoğlu, Rıza
Frieg, Benedikt
Dienemann, Christian
Leonov, Andrei
Nimerovsky, Evgeny
Sant, Vrinda
Ryazanov, Sergey
Giese, Armin
Schröder, Gunnar F.
Becker, Stefan
de Groot, Bert L.
Griesinger, Christian
Andreas, Loren B.
The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils
title The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils
title_full The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils
title_fullStr The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils
title_full_unstemmed The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils
title_short The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils
title_sort clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474542/
https://www.ncbi.nlm.nih.gov/pubmed/36104315
http://dx.doi.org/10.1038/s41467-022-32797-w
work_keys_str_mv AT antonschmidtleif theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT matthesdirk theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT dervisoglurıza theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT friegbenedikt theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT dienemannchristian theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT leonovandrei theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT nimerovskyevgeny theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT santvrinda theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT ryazanovsergey theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT giesearmin theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT schrodergunnarf theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT beckerstefan theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT degrootbertl theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT griesingerchristian theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT andreaslorenb theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT antonschmidtleif clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT matthesdirk clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT dervisoglurıza clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT friegbenedikt clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT dienemannchristian clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT leonovandrei clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT nimerovskyevgeny clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT santvrinda clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT ryazanovsergey clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT giesearmin clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT schrodergunnarf clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT beckerstefan clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT degrootbertl clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT griesingerchristian clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils
AT andreaslorenb clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils